Loading...

Pear Therapeutics, Inc.

PEARW•NASDAQ
Healthcare
Medical - Healthcare Information Services
$0.006
$0.00(0.00%)

Pear Therapeutics, Inc. (PEARW) Stock Overview

Explore Pear Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

C+

Score: 58.4/100

Key Financials

Market Cap4.1M
P/E Ratio-0.17
EPS (TTM)$-10.10
ROE-0.39%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

PEARW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Pear Therapeutics, Inc. (PEARW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.17 and a market capitalization of 4.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PEARWStats details for PEARW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PEARWAnalyst Recommendations details for PEARW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.

CEO

Corey M. McCann

Employees

200

Headquarters

200 State Street, Boston, MA

Founded

1970

Frequently Asked Questions

;